Topic: Antibody Therapy & Second Boosters: Updates and Perspectives on Protecting Our Most Vulnerable
Moderator:
Dana S. Wollins, DrPH, MGC
Vice President, Clinical Affairs & Practice Guidelines, IDSA
Update: New Resources to Manage Paxlovid Drug Interactions
Carlos del Rio, MD, FIDSA
President-Elect, IDSA
Distinguished Professor of Medicine, Division of Infectious Diseases
Emory University School of Medicine
Professor of Epidemiology & Global Health
Rollins School of Public Health of Emory University
Topics and Featured Experts:
Prevention of COVID-19 in Immunocompromised Individuals: Focus on Evusheld
Clinical Considerations & Patient Scenarios
Camille Kotton, MD, FIDSA, FAST
Clinical Director
Transplant & Immunocompromised Host Infectious Diseases
Massachusetts General Hospital
Utilization Update & Strategies to Improve Access
Derek Eisnor, MD
Medical Officer, Division of Clinical Development
Biomedical Advanced Research and Development Authority
COVID-19 Allocation and Distribution Lead
U.S. Department of Health & Human Services
Lessons Learned and Success Stories
Swana K. Thomas, PharmD, MPH
Clinical Pharmacist, Ambulatory Care
Geisinger Health System
Monoclonal Antibody Therapy for Treatment: What are the Options?
Raymund R. Razonable, MD
Professor of Medicine
Vice Chair, Infectious Diseases
Mayo Clinic
Second Boosters: Who Will Benefit?
Updates & Clinical Considerations from the April 20 ACIP Meeting
Elisha Hall, PhD, RD
Lead, Clinical Guidelines
Vaccine Task Force
COVID-19 Response
Centers for Disease Control and Prevention
Perspectives on the Immunocompromised & People Over 50
William Schaffner, MD
Professor of Preventative Medicine, Department of Health Policy
Professor of Medicine, Division of Infectious Diseases
Vanderbilt University School of Medicine
